Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis

Nina-Sophie Hegemann¹*, Anne Schlesinger-Raab⁷, Ute Ganswindt¹, Claudia Hörl³, Stephanie E. Combs⁴,⁵, Dieter Hölzel⁷, Jürgen E. Gschwend⁶, Christian Stief⁷, Claus Belka¹† and Jutta Engel²†

Abstract

Background: To investigate the risk of second cancer and radiation induced second cancer following prostate cancer radiotherapy.

Methods: We compared men with radiotherapy only with those treated with radical prostatectomy only and those with radiotherapy after radical prostatectomy. Cumulative incidences of second cancers were calculated. Cox analyses were performed to identify determinants influencing second cancer incidence.

Results: Nineteen thousand five hundred eighty patients were analyzed. Age and median follow-up differed significantly with radiotherapy only patients having the highest median age (70.3 years) and radical prostatectomy only patients the longest median follow-up (10.2 years). Ten-year cumulative incidence of second cancer was 15.9%, 13.2% and 10.5% for patients with radiotherapy only, radiotherapy after radical prostatectomy and radical prostatectomy only (p<0.0001). Increasing age and belonging to the radiotherapy only group were associated with a higher risk of second cancer—no significant increase was seen in radiotherapy after radical prostatectomy patients. A significantly higher rate of smoking related malignancies, like lung, bladder and non-melanoma skin cancer, was seen in radiotherapy only patients.

Conclusions: No clear increase in radiation induced second cancer was found in patients after radiotherapy for prostate cancer. Whereas the rate of second cancer was increased in radiotherapy only patients, no such increase was seen in patients with radiotherapy after radical prostatectomy. The increase of second cancer following radiotherapy only is highly likely to reflect advanced age and lifestyle habits and comorbidities.

Keywords: Second cancer, Radiotherapy, Prostate cancer

Background

Radiation induced second cancers (RISC) are rare but relevant late effects of radiation therapy (RT) [1, 2]. In principle most of the knowledge regarding RISC is derived from epidemiological data of atomic bomb survivors, nuclear accidents and database analyses [3]. Since there are no biological markers available allowing for a precise discrimination between RISC and non-radiation induced second cancer (SC), all assessments are based on epidemiological and/or statistical analysis. In principle, RISCs are defined as those cancers occurring inside or close to radiation exposed regions (field congruence) [4] and after a longer lag time (>10 years in some publications even >15 years) [5, 6]. However, in real world settings the determination of SC risks—and especially RISC risks—after therapeutic exposures is strongly limited by several factors: Heterogeneous patient cohorts, small sample sizes, complex influence of confounders and lacking data. Nevertheless, in case of Hodgkin’s lymphoma and breast cancer several trials document an increase in SC and RISC [7–9]. The risk of lung cancer after breast RT is considerably low in non-smokers (Odds ratio 1), however an increase (25-fold) was detected in smokers [10]. Thus
RISC in this setting is triggered mainly by synergisms with a strong confounding factor.

In case of prostate cancer (PCa) patients being long-term cancer survivors [11] no clear picture emerges from all available data [12, 13]. Previous reports on the incidence of RISC using either Surveillance, Epidemiology, and End Results (SEER) or registry information provide conflicting results, whether after RT an increased risk of SC in PCa patients exists [14–25] or not [26–28]. With the help of the population-based Munich Cancer Registry (MCR) we attempted to gain further insight into SC risk after RT of PCa.

Methods
Data collection
The MCR is a population-based clinical cancer registry in Bavaria (Southern Germany) comprising 4.6 million inhabitants [29]. A total of 42,449 patients with PCa were registered from 1988 to 2008 (Fig. 1). Patients with lymphoma (n = 5) or sarcoma (n = 5) of the prostate, or with death certificate only (DCO) (n = 2,627) and men with evidence of a previous or synchronous malignant tumor (n = 4,217) were excluded. Of 35,595 patients with invasive PCa, 14,289 received radical prostatectomy (RPE only), 3,883 received radiation therapy (RT only) and 1,366 got radiation therapy after radical prostatectomy (RT after RPE). All analyses were performed on 19,538 patients (RPE only, RT only or RT after RPE). This analysis was in conformity with the Declaration of Helsinki (Sixth Revision, 2008) and was exempt from ethics approval. Bavarian state law allows the use of patient data for research, provided that person related data are made anonymous.

Statistical analysis
The MCR organizes data in an Oracle database (Oracle, Belmont, CA) and uses Statistical Analysis Software, version 9.2 (SAS Institute, Cary, NC). The percentages of the presented subcategories are related to the sum of each item with available data; missing values are not taken into account. The significance level was set at 5%. Median follow-up was calculated for patients alive. To account for competing risks (e.g. death), the different age distribution between the three treatment groups and differences in follow-up cumulative incidence function according to Kalbfleisch and Prentice was used to calculate time to SC. Cancers occurring within the first year after treatment for PCa were not considered as SC. Differences in cumulative incidence among the three treatment groups were assessed by Gray’s test. Independent prognostic factors influencing time to SC were investigated by Cox proportional hazard regression. The proportional hazard assumption was visually checked by log-log plots. Hazard ratios, 95% confidence intervals (CI) and p-values acquired by Global Wald test are presented. The following factors were included simultaneously as independent variables modeling the incidence of SC in total in the multivariate analysis: age (<60, 60 – <65, 65 – <70, 70 – <75, ≥75 years), T- (T1, T2, T3, T4), N- (N0, N+, NX) and M-category (M0, M1) and treatment (RPE only, RT only and RT after RPE). Cox proportional hazard regression was also used to calculate models for the incidence of the most common tumor entities adjusted for the covariates mentioned above.

Results
Overall cumulative incidence and location of second cancer
Table 1 lists the characteristics of the cohort with RT only or with RT after RPE compared to the surgical control group (RPE only). Patients with RT only had a higher median age (70.3 years) than patients with RPE only (65.2 years) or RT after RPE (64.4 years). Tumor characteristics were equally distributed between the three groups. Median follow-up between the three groups was significantly different with 10.2, 9.6 and 8.8 years in patients with RPE only, RT only or RT after RPE. Since previous studies on atomic bomb survivors estimated an average latency time of 5–15 years for RISC, analyses were done for SC occurring >10 years and >20 years [5, 6]. The cumulative incidence of SC was 15.9%, 13.2% and 10.5% after 10 and 26.7%, 26.6% and 23.7% after 20 years for patients with RT only, RT after RPE and RPE only (p<0.0001). The most frequent sites of SC were colon, rectal, lung, bladder and non-melanoma skin cancer (Table 2) significantly differently distributed between the treatment groups. After 10 years, colon cancer was observed with a cumulative incidence of 2.0% in RT after RPE followed by RT only (1.7%) and RPE only (1.1%) (Fig. 2a). Rectal cancer occurred more often in RT only (1.1%) than in RPE only (0.6%) and RT
after RPE (0.3%) (Fig. 2a). The cumulative incidence of lung cancer was 2.2% after RT only and 1.2% in surgical patients regardless of postoperative RT (Fig. 2b). Bladder cancer was seen with a cumulative incidence of 2.7%, 1.5% and 1.1% in RT only, RT after RPE and RPE only (Fig. 2c). Non-melanoma skin cancer was observed with a cumulative incidence of 2.1%, 1.6% and 1.2% in RT only, RT after RPE and RPE only (Fig. 2d).

Factors influencing incidence of second cancer
Table 3 shows the results of the Cox analysis for SC in total with age, T-, N- and M-category and treatment as influencing factors. Age, T- and N-category and treatment were predictors for SC development. Increasing age was significantly associated with a higher risk of SC. RT only patients remained at a significantly higher risk of SC (HR 1.404) compared to patients with RPE only (HR 1) or RT after RPE (HR 1.314). Already metastasized patients at initial treatment were at lower risk of SC due to their shortened life span. Analyzing the most frequent sites of SC separately adjusted for the abovementioned confounder variables treatment group remained a significant factor (Table 4). RT after RPE patients were at the highest risk of developing colon cancer compared to the other two treatment groups. Regarding rectal cancer, RT only patients (HR 1.751) were at highest risk and patients with RT after RPE were less at risk (HR 0.638) compared to RPE only patients (HR 1). RT only patients were at high risk (HR 1.733) of lung cancer during follow up. Hazard ratios regarding lung cancer of patients with RPE only (HR 1) or RT after RPE (HR 1.017) did not differ: Fig. 2b demonstrates no difference in cumulative probability of lung cancer after 10 years between patients with RPE only or RT after RPE. Likewise the risk of bladder cancer was significantly higher for RT only patients (HR 2.098) in contrast to a lower probability in patients with RT only (HR 1) or RT after RPE (HR 0.638) compared to RPE only patients (HR 1). RT only patients were at high risk (HR 1.733) of lung cancer during follow up. Hazard ratios regarding lung cancer of patients with RPE only (HR 1) or RT after RPE (HR 1.017) did not differ: Fig. 2b demonstrates no difference in cumulative probability of lung cancer after 10 years between patients with RPE only or RT after RPE. Likewise the risk of bladder cancer was significantly higher for RT only patients (HR 2.098) in contrast to a lower probability in patients with RT only (HR 1) or RT after RPE (HR 0.638) compared to RPE only patients (HR 1). This was also observed for non-melanoma skin cancer (Fig. 2d) with RT only patients (HR 1.658) being at highest risk compared to the other two treatment arms (HR RPE only 1 and HR RT after RPE 1.305). Analysis of the most frequent sites of SC revealed a significantly increased rate of smoking and age related cancer entities, like lung, bladder and non-melanoma skin cancer in RT only patients.

Discussion
The present study compares the incidence of SC in patients treated with RT only or RT after RPE to a surgical control group (RPE only). Two key findings emerged: First, the rate of smoking related cancer entities is increased in RT only patients but not in patients with RT after RPE. Secondly, patients who do receive RT as curative treatment are generally older probably

| Table 1 Patient characteristics |
| Treatment | RPE only | RT only | RT after RPE |
| --- | --- | --- | --- |
| | N | % | N | % | N | % |
| All | 14289 | 100.0 | 3883 | 100.0 | 1366 | 100.0 |
| Age [yrs] | | | | | | |
| median | 65.2 | 70.3 | 64.4 | | | |
| < 60 | 3208 | 22.5 | 367 | 9.5 | 356 | 26.1 | | | | |
| 60–64 | 3758 | 26.3 | 599 | 15.4 | 364 | 26.6 | | | | |
| 65–69 | 4391 | 30.7 | 903 | 23.3 | 412 | 30.2 | | | | |
| 70–74 | 2432 | 17.0 | 1135 | 29.2 | 199 | 14.6 | | | | |
| > =75 | 500 | 3.5 | 879 | 22.6 | 35 | 2.6 | | | | |
| Risk Group | | | | | | |
| low riska | 1843 | 13.2 | 529 | 17.0 | 35 | 2.6 | | | | |
| intermediate riskb | 3051 | 21.9 | 665 | 21.4 | 162 | 12.1 | | | | |
| highriskc | 6130 | 44.1 | 1067 | 34.3 | 504 | 37.8 | | | | |
| locally advancedd | 2615 | 18.8 | 738 | 23.8 | 522 | 39.1 | | | | |
| advanced (N+) | 275 | 2.0 | 108 | 3.5 | 112 | 8.4 | | | | |
| metastasized (M1) | 54 | 0.4 | 401 | 11.4 | 20 | 1.5 | | | | |
| Missinge | 321 | 2.2 | 375 | 9.7 | 11 | 0.8 | | | | |
| T-category | | | | | | |
| T1 | 1852 | 13.4 | 586 | 19.2 | 146 | 10.9 | | | | |
| T2 | 9152 | 66.0 | 1508 | 49.5 | 563 | 42.1 | | | | |
| T3 | 2724 | 19.6 | 784 | 25.7 | 565 | 42.3 | | | | |
| T4 | 139 | 1.0 | 170 | 5.6 | 62 | 4.6 | | | | |
| Missinge | 422 | 3.0 | 835 | 21.5 | 30 | 2.2 | | | | |
| N-category | | | | | | |
| N0 | 9008 | 65.2 | 2046 | 67.3 | 869 | 64.6 | | | | |
| N+ | 346 | 2.5 | 198 | 6.5 | 128 | 9.5 | | | | |
| NX | 4460 | 32.3 | 794 | 26.1 | 348 | 25.9 | | | | |
| Missinge | 475 | 3.3 | 845 | 21.8 | 21 | 1.5 | | | | |
| M-category | | | | | | |
| M0 | 14235 | 99.6 | 3482 | 89.7 | 1346 | 98.5 | | | | |
| M1 | 54 | 0.4 | 401 | 10.3 | 20 | 1.5 | | | | |
| Second Cancer (p < 0.0001) | | | | | | |
| developed | 1876 | 638 | 186 | | | | | | | |
| CI after 10 years | 10.5 | 15.9 | 13.2 | | | | | | | |
| CI after 20 years | 23.7 | 26.7 | 26.6 | | | | | | | |
| Median follow-up of survivors [yrs] (p < 0.0001) | 10.2 | 9.6 | 8.8 | | | | | | | |

CI cumulative incidence
a low risk: PSA ≤ 10 ng/ml and Gleason score ≤ 6 and T1 to T2a (without T2)

b intermediate risk: PSA >10 – 20 ng/ml or Gleason=7 or T2b
c high risk: PSA > 20 ng/ml or Gleason score ≥ 8 or T2c
d locally advanced: T3-4

The percentage of the subcategories is related to the sum of each item with available data; missing values are not taken into account
harboring more comorbidities than patients undergoing surgery [30]. This implies that there are more confounders than age, T-, N- and M-category and treatment that influence the differing incidence of SC between the three treatment arms.

In accordance with literature [14–16, 18, 19, 24], an increased incidence of SC after 10 years has been seen in RT only patients (15.9%) vs. patients with RPE only (10.5%) or RT after RPE (13.2%). Differences in SC incidence between the cohorts should not be attributed to different median follow-up, as this has been taken into account by calculating cumulative incidence rates according to Kalbfleisch and Prentice. The cumulative incidence function by Kalbfleisch and Prentice does not only consider different follow up time but also considers the different age distribution between the three treatment groups and death as a competing risk factor. Cox analysis revealed that especially increasing age and being treated by RT only are the main predictive factors for a higher overall SC incidence.

| Table 2 Cumulative incidence of most common cancer entities after 10 years of follow-up |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                 | RPE only [%]    | RT only [%]     | RT after RPE [%]| p-value*        |
| All second cancer               | 10.5            | 15.9            | 13.2            | <.0001          |
| Colon cancer                    | 1.1             | 1.7             | 2.0             | 0.0017          |
| Rectal cancer                   | 0.6             | 1.1             | 0.3             | 0.0036          |
| Lung cancer                     | 1.2             | 2.2             | 1.2             | <.0001          |
| Bladder cancer                  | 1.1             | 2.7             | 1.5             | <.0001          |
| Non-melanoma skin cancer        | 1.2             | 2.1             | 1.6             | <.0001          |

*aTo account for competing risks, like death, cumulative incidence analysis was used to calculate time to second malignancy

*p-value was calculated by Gray-Test

Fig. 2 a-d: Cumulative incidences of colorectal, lung, bladder and non-melanoma skin cancer stratified by treatment arms (RPE only, RT only, RT after RPE)
When analyzing the situation for those SC sites in close proximity to the radiation portals (rectal, colon and bladder cancer) a complex picture emerges: At first glance, the rate of SC is increased after RT only – however no such increase is detectable in patients receiving both RPE and RT with the lowest absolute rate of rectal cancer being visible in patients having had both treatments. Based on pure reasoning, it seems therefore unlikely that radiation is really causal for the observed effect in RT only patients. The low number of events even in a large cohort will limit any valid risk assessment: In patients with RT only (HR 1.751) there was a 70% higher risk of rectal cancer compared to patients treated with RPE only (HR 1) and a less increased risk of colon cancer (HR 1.326 for RT only vs. HR 1 for RPE only). The diverging HRs of patients with RT after RPE with decreased risk of rectal (HR 0.638) and increased risk of colon cancer (HR 1.903) can be partially explained by the few events in the small group of patients with RT after RPE, which can also be seen in the wide 95% CI. Similarly, most other trials were not able to unequivocally document any increase in the incidence of colorectal cancer after RT [17, 25–27, 31–33]. Kendal et al. reported that an increased frequency of rectal cancer after irradiation is apparent on crude analysis, but age as an important confounder has to be taken into account. After adjustment for age these differences were no longer observable [26, 32]. Globally, our Cox regression analysis also revealed that age as a covariate generally plays a significant role in the development for SC at any site including colorectal SC (Hazard Ratio 1.278 in 60 –<65 year old patients vs. 2.177 in ≥75 year old patients, p<0.0001). Taken together our data do not indicate that RT is associated with a relevant risk of SC induction in the colorectum.

Similar to the colorectal mucosa variable parts of the bladder are exposed to radiation. Thus the bladder is also at risk for RISC. In our trial the 10-year cumulative incidence of bladder cancer was low with 2.7% in RT only, 1.5% in postoperative RT and 1.1% in RPE only patients. Cox analysis revealed that the RT only group (HR 2.098) had the highest risk of bladder cancer.
compared to the surgically treated patients. Similar to the findings for colorectal SC, combined treatment was associated with a lower incidence of bladder SC compared to RT only. Thus again our data failed to document an unequivocal increase in bladder RISC. In contrast the SEER analysis of Singh et al. showed a significant difference in the crude incidence rate of bladder cancer when comparing RT vs. surgery alone. On multivariate analysis in this study, age and irradiation were highly significant predictors of being diagnosed with bladder cancer [20]. As smoking data are absent from the SEER database, it was not possible to adjust for this confounder. In a recent report, Zelefsky et al. presented the 10-year likelihood rates for bladder cancer in patients treated with RPE or RT. One of the key messages of this trial is that patients treated with RT were older and had more serious comorbidities, many of them related to smoking. After Cox regression analysis, only age and history of smoking were significant predictors for the development of SC in this trial [27]. Likewise, Hamilton et al. came to a similar conclusion after comparing patients with brachytherapy and radical prostatectomy to the general population [34]: Older age and smoking were associated with an increased SC risk. Radical prostatectomy was not associated with a decreased pelvic malignancy risk, even when excluding patients with post-prostatectomy RT.

In addition to SC in close proximity to the primary radiation fields, several groups also explored the rate of SC outside the direct treatment areas.

In a recent report, Donin et al. presented the most common sites of SC among cancer survivors from SEER database [35]. Like in our cohort, the most commonly diagnosed SC among PCa survivors was lung (20.1%), colorectal- (15.5%) and bladder cancer (13.2%). Thus, smoking related cancers dominate the SC rates. A shortcoming of the data by Donin et al. is the missing correlation of SC rate with the respective treatment. The cumulative incidence of lung cancer in our cohort was 2.2% after RT only whereas it was the same (1.2%) in patients with RPE only or RT after RPE. Thus again, our data substantially indicate that SC in patients with RT only is related to a strong selection bias rather than indicating a real risk of SC after RT. Mainly patients being not fit for surgery will be selected for RT with smoking related disorders and age being major reasons [30, 36].

Smoking habits were not uniformly registered in MCR and could therefore not be used in the Cox analysis. We can therefore only hypothesize that smoking prevalence and its related comorbidities were higher in the generally older RT only patients. Depending on the prevalence, tobacco use alone could account for the observed 1.0% increase in cumulative incidence of lung cancer seen in the RT only group [37].

Apart from the abovementioned cancer entities, a single report documented an increase of non-melanoma skin cancer: Zelefsky et al. showed higher rates of skin cancer in patients with external beam RT compared to the general population or to patients who received brachytherapy. Apparently this is due to low-dose radiation from internally scattered X-rays, leakage of X-rays from the machine and/or neutron production, especially observed after doses ≥10 MV photons [38]. Apart from skin cancer Zelefsky et al. could not find any excessive risk of SC [21]. In contrast, no such increase was detectable in the RT after RPE group from our analysis indicating that the small increase in non-melanoma skin cancer in RT only patients may be attributed to other factors than the use of RT [39].

The high complexity of interacting confounding factors can be seen when the data of the large Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial is taken into account: At first glance, patients after RT had increased risks for any SC (incidence 15.5/1000 person-years in irradiated patients vs. 11.4/1000 person-years in non-irradiated patients) with a substantial increase in lung cancer (RR 1.6, 95% CI 1.1-2.4). However, after adjusting for age, race, education, family history of cancer, COPD and smoking no increase for second colorectal or bladder cancer was documented any longer. Based on simple reasoning, it seems highly unlikely that no such increase occurs in close proximity to the radiation exposure, whereas a substantial increase occurs in far distant regions with only minimal radiation exposure. This interpretation is corroborated further by the fact that after breast irradiation with relevant part of the lungs being exposed, only a very low risk of SC is documented in non-smokers [10].

Most studies on RISC are based on pooled data sets. Inherently biases and confounders blur the interpretation of these results. A Dutch group analyzed the incidence rate of SC for patients prospectively treated in the TME trial, the PORTEC-1 and PORTEC-2 trial. The number of events (SCs) was much lower and however no significant increase for any pelvic or non-pelvic RISC was found [33].

All in all, up to now no consistent increased risk for SC after RT has been published. Most trials, like ours are based on retrospective data analyses with inherent shortcomings: Major confounders (e.g. smoking habits) have not been documented, treatment decisions (RT vs. no-RT) are mainly based on subjective and ill-defined parameters leading to strong biases, radiobiological inconsistencies exist with patient receiving a combined treatment of RT and surgery displaying the lowest rate of SC in some data sets and crude SC rates outside the radiation fields are higher than in close proximity to the exposed areas. With RT only patients having the highest
number of SC cumulative incidence, a correlation between dose and SC incidence in patients treated with RT only or with RT after RPE with assuming different overall doses would have been interesting. Unfortunately in the MCR only limited information regarding the type of radiation delivery, the dosage and fields is given. We tried to overcome these shortcomings by using the cumulative incidence function according to Kalbfleisch and Prentice as an elaborate statistical method that accounts for death as a competing risk factor, the different age distribution and differences in follow-up between the three treatment arms.

In this regard a commentary from Kendal et al. on data provided by Moon et al. [40] nicely summarizes all these shortcomings with his own observation that no increase of RISC is detectable in 520,708 SEER cases with PCAs after appropriate statistical considerations of age shifts (attained age) and other major factors [32]. Accordingly, Murray et al. [1] also pinpoints that differences between comparison groups, as well as differences in length of follow-up between treatment groups and failure to adequately correct for duration of follow-up may result in inaccurate conclusions.

Conclusions
Our data suggest that RT does not increase the risk of SC. The increase of SC seen in patients with RT only in our cohort needs to be attributed to confounders suggested by an increased rate of smoking related malignancies. This interpretation is corroborated by the fact that no such increase was seen in patients treated with RT after RPE. At present we do recommend to inform patients about the negligible risk. However, it seems extremely important to ensure that the information given enables patients to realistically balance the value of the treatment against the risks. For any future trial it seems mandatory to carefully and prospectively document confounding comorbidities and lifestyle habits when attempting to gain a detailed and realistic insight into the risk of SC in PCA patients.

Abbreviations
CI: Confidence intervals; COPD: Chronic obstructive pulmonary disease; DCO: Death certificate only; HR: Hazard Ratio; MCR: Munich Cancer Registry; PCA: Prostate cancer; PLCO trial: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; PORTEC-1/2: Postoperative Radiation Therapy in Endometrial Carcinoma 1/2; RISC: Radiation induced second cancer; RPE only: Radical prostatectomy; RT: radiation therapy; RT after RPE: Radiation therapy after radical prostatectomy; RT only: Radiation therapy only; SC: Second cancer; SEER: Surveillance, Epidemiology, and End Results; TME: Total mesorectal excision

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
Data and materials are fully available and presented in the main paper.

Authors’ contributions
NSH, CB and UG are responsible for analysis and interpretation of data and drafting and revising the manuscript. JE, DH and ASR have been involved in acquisition, analysis and interpretation of data. CH, SEC, JEG and CS have revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This retrospective study was exempt from requiring ethics approval. Bavarian state law (Bayrisches Krankenhausgesetz/Bavarian Hospital Law §27 Absatz 4 Datenschutz (Dataprotection)) allows the use of patient data for research, provided that any person’s related data are kept anonymous. German radiation protection laws request a regular analysis of outcomes in the sense of quality control and assurance, thus in the case of purely retrospective studies no additional ethical approval is needed under German law.

Author details
1Department of Radiation Oncology, Klinikum der Universität, Ludwig-Maximilians-University, LMU Munich, Marchioninistr 15, 81377 Munich, Germany. 2Munich Cancer Registry (MCC) at the Department of Medical Informatics, Biometry and Epidemiology (IBE), University of Munich, Marchioninistr 15, 81377 Munich, Germany. 3Department of Radiotherapy, Klinikum Schwabing, Kölner Pl 1, 80804 Munich, Germany. 4Department of Radiation Oncology, Klinikum Rechts der Isar, Technical University (TU), Ismaningerstr 22, 81675 Munich, Germany. 5Institute of Innovative Radiotherapy (iRT), Helmholtz Centre, Munich, Germany. 6Department of Urology, Klinikum Rechts der Isar, Technical University (TU), Ismaningerstr 22, 81675 Munich, Germany. 7Department of Urology, Klinikum der Universität, Ludwig-Maximilians-University, LMU Munich, Marchioninistr 15, 81377 Munich, Germany.

Received: 19 October 2016 Accepted: 6 December 2016
Published online: 03 January 2017

References
1. Murray L, Henry A, Hoskin P, Siebert F-A, Venselaar J. Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique. Radiother Oncol. 2014;110:213–28.
2. Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J. Second primary cancers after radiation for prostate cancer: a review of data from planning studies. Radiat Oncol. 2013;8:172.
3. Moseenko V, Khvostunov IK, Hattangadi-Gluth JA, Muren LP, Lloyd DC. Biological dosimetry to assess risks of health effects in victims of radiation accidents: Thirty years after Chernobyl. Radiat Oncol. 2016;11:191–4.
4. Zhang R, Mirkovic D, Newhauser WD. Visualization of risk of radiogenic second cancer in the organs and tissues of the human body. Radiat Oncol. 2015;10:107.
5. Thompson DE, Malbuchi K, Ron E, Sia D, Tokunaga M, Ochi K, et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958–1987. Radiat. Res. 1994;137:511–67.
6. Li C, Nishi N, McDougall JA, Semmens E, Sugiyama H, Hoskin P, et al. Relationship between radiation exposure and risk of second primary cancers among atomic bomb survivors. Cancer Res. 2010;70:7187–98.
7. Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol. 2015;114:56–65.
8. Schaapveld M, Aleman BPM, van Eggermont AM, Janus CPM, Krol ADG, van der Maazen RWM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med. 2015;373:2499–511.
9. Finke I, Scholz-Kreisel P, Hennewig U, Blettner M, Spix C. Radiotherapy and subsequent thyroid cancer in German childhood cancer survivors: a nested case–control study. Radiat Oncol. 2015;10:219.

10. Grantzau T, Thomesen MS, Vaeth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother Oncol. 2014;113:366–73.

11. Hall MD, Schultheiss TE, Smith DD, Tseng BP, Wong JY. The impact of increasing dose on overall survival in prostate cancer. Radiat Oncol. 2015;10:115.

12. Müller AC, Ganswindt U, Bamberg M, Belka C. Risk of second malignancies after prostate irradiation? Strahlenther Onkol. 2007;183:605–9.

13. Wallis CJ, Mahler AL, Choo R, Hershorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BJU Int. 2016;35:185.

14. Abdel-Wahab M, Reis M, Wu J, Duncan R. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urorol. 2009;74:866–71.

15. Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of secondary primary tumors in men diagnosed with prostate cancer: A population-based cohort study. Cancer. 2014;120:2735–41.

16. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88:398–406.

17. Huang J, Kestin LL, Ye H, Wallace M, Martinez AA, Vicini FA. Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol. 2011;98:61–6.

18. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: A population-based study. Gastroenterology. 2005;128:819–24.

19. Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008;180:2005–9.

20. Singh AK, Mashtare TL, McCloskey SA, Seixas-Mikelus SA, Kim HL, May KS. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis. Int J Radiat Oncol Biol Phys. 2010;78:1086–94.

21. Zelensky MJ, Housman DM, Pei X, Alicikus Z, Magaiano JM, Dauer LT, et al. Incidence of secondary cancers after high-dose-intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83:953–9.

22. Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984–2000. Radiother Oncol. 2002;65:145–51.

23. Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, et al. The rate of secondary malignancies after intensity-modulated radiotherapy versus external beam radiation therapy for localized prostate cancer: A population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys. 2010;76:642–48.

24. Berrington de Gonzalez A, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:535–60.

25. Abdel-Wahab M, Reis M, Hamilton K. Second primary cancer after radiotherapy for prostate cancer—A seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:58–68.

26. Kendal WS, Eapen L, Macrae R, Malone S, Nicholas G. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:661–8.

27. Zelensky MJ, Pei X, Teslova T, Kuk D, Magaiano JM, Kollmeier M, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int. 2012;110:1696–701.

28. Chrousos K, Lébovitch B, Ben-Galit I, Zincke H, Blute ML. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2008;179:57–511.

29. Munich Cancer Registry (MCR). http://www.tumorregister-muenchen.de. Accessed 17 Oct 2016.

30. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer. 2012;15:374–9.

31. Heilwell GO, Dearden JC. What are the risks of second cancer formation after radiotherapy to the prostate? BJU Int. 2007;99:698.